Top

Journal of Ovarian Research

Published in:

Open Access 01-12-2015 | Research

Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer

Authors: Andrew J. Wilson, Jeanette Saskowski, Whitney Barham, Fiona Yull, Dineo Khabele

Published in: Journal of Ovarian Research | Issue 1/2015

Abstract

Background

Ovarian cancer is the most lethal gynecologic malignancy characterized by the frequent development of resistance to platinum chemotherapy. Finding new drug combinations to overcome platinum resistance is a key clinical challenge. Thymoquinone (TQ) is a component of black seed oil that exerts multiple anti-tumorigenic effects on cells, including inhibition of NF-κB and promotion of DNA damage. We aimed to determine whether TQ enhances cisplatin cytotoxicity in cultured ovarian cancer cells and in an established murine syngeneic model of ovarian cancer.

Methods

Ovarian cancer cell viability in vitro was measured by sulforhodamine B (SRB) assays, and drug interactions tested for synergism by isobologram analysis. ID8-NGL mouse ovarian cancer cells stably expressing an NF-κB reporter transgene were injected intra-peritoneally into C57BL/6 mice. After 30 day TQ and/or cisplatin treatment, we measured the following indices: tumor burden (ascites volume, number of peritoneal implants and mesenteric tumor mass); NF-κB reporter activity (luciferase assay); protein expression of the double-strand DNA break marker, pH2AX(ser139), the proliferation markers, Ki67/mib-1 and PCNA, and the apoptosis markers, cleaved caspase-3, cleaved PARP and Bax; and mRNA expression of NF-κB targets, TNF-α and IL-1β. Two-tailed Mann–Whitney tests were used for measuring differences between groups in mouse experiments.

Results

In SRB assays, TQ and cisplatin synergized in ID8-NGL cells. In mice, cisplatin significantly reduced cell proliferation and increased apoptosis in tumors, resulting in decreased overall tumor burden. Combining TQ with cisplatin further decreased these indices, indicating co-operative effects between the drugs. TQ treatment promoted cisplatin-induced pH2AX expression in cultured cells and in tumors. While NF-κB inhibition by TQ induced anti-tumor effects in vitro, we made the unexpected observation that TQ alone increased both tumor NF-κB activity and formation of ascites in vivo.

Conclusions

TQ enhanced cisplatin-mediated cytoxicity in ovarian cancer cells in vitro and in a mouse syngeneic model, effects associated with increased DNA damage. However, our results strongly caution that TQ treatment alone may have an overall deleterious effect in the immunocompetent host through stimulation of ascites. Since TQ is a potential candidate for future clinical trials in ovarian cancer patients, this finding has considerable potential relevance to the clinic.

Available only for authorised users

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. doi:10.3322/caac.21254.PubMedCrossRef

Bast Jr RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9(6):415–28. doi:10.1038/nrc2644.PubMedCentralPubMedCrossRef

Muggia F. Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecol Oncol. 2009;112(1):275–81. doi:10.1016/j.ygyno.2008.09.034.PubMedCrossRef

Sethi G, Ahn KS, Aggarwal BB. Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol Cancer Res. 2008;6(6):1059–70. doi:10.1158/1541-7786.MCR-07-2088.PubMedCrossRef

Ahmad A, Husain A, Mujeeb M, Khan SA, Najmi AK, Siddique NA, et al. A review on therapeutic potential of Nigella sativa: a miracle herb. Asian Pac J Trop Biomed. 2013;3(5):337–52. doi:10.1016/S2221-1691(13)60075-1.PubMedCentralPubMedCrossRef

Rahmani AH, Alzohairy MA, Khan MA, Aly SM. Therapeutic implications of black seed and its constituent thymoquinone in the prevention of cancer through inactivation and activation of molecular pathways. Evid Based Complement Alternat Med. 2014;2014:724658. doi:10.1155/2014/724658.PubMedCentralPubMedCrossRef

Abukhader MM. Thymoquinone in the clinical treatment of cancer: fact or fiction? Pharmacogn Rev. 2013;7(14):117–20. doi:10.4103/0973-7847.120509.PubMedCentralPubMedCrossRef

Hernandez L, Hsu SC, Davidson B, Birrer MJ, Kohn EC, Annunziata CM. Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer Res. 2010;70(10):4005–14. 10.1158/0008-5472.CAN-09-3912.PubMedCentralPubMedCrossRef

Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, et al. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature. 2009;462(7269):104–7. doi:10.1038/nature08462.PubMedCentralPubMedCrossRef

10.

Karin M. The IkappaB kinase–a bridge between inflammation and cancer. Cell Res. 2008;18(3):334–42. doi:10.1038/cr.2008.30.PubMedCrossRef

11.

Balkwill F, Coussens LM. Cancer: an inflammatory link. Nature. 2004;431(7007):405–6. doi:10.1038/431405a.PubMedCrossRef

12.

Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell. 2004;6(3):203–8. doi:10.1016/j.ccr.2004.09.003.PubMedCrossRef

13.

Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7. doi:10.1038/nature01322.PubMedCentralPubMedCrossRef

14.

Al-Amri AM, Bamosa AO. Phase I safety and clinical activity study of thymoquinone in patients with advanced refractory malignant disease. Shiraz E-Med J. 2009;10(3):107–11.

15.

Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–83. doi:10.1038/onc.2011.384.PubMedCrossRef

16.

Miow QH, Tan TZ, Ye J, Lau JA, Yokomizo T, Thiery JP, et al. Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer. Oncogene. 2014. doi:10.1038/onc.2014.136.PubMed

17.

Gilmore TD, Herscovitch M. Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene. 2006;25(51):6887–99. doi:10.1038/sj.onc.1209982.PubMedCrossRef

18.

DelloRusso C, Welcsh PL, Wang W, Garcia RL, King MC, Swisher EM. Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation. Mol Cancer Res. 2007;5(1):35–45. doi:10.1158/1541-7786.MCR-06-0234.PubMedCrossRef

19.

Wilson AJ, Holson E, Wagner F, Zhang YL, Fass DM, Haggarty SJ, et al. The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells. Cancer Biol Ther. 2011;12(6):484–93. doi:10.4161/cbt.12.6.15956.PubMedCentralPubMedCrossRef

20.

Wilson AJ, Lalani AS, Wass E, Saskowski J, Khabele D. Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer. Gynecol Oncol. 2012;127(3):579–86. doi:10.1016/j.ygyno.2012.09.016.PubMedCentralPubMedCrossRef

21.

Wilson AJ, Barham W, Saskowski J, Tikhomirov O, Chen L, Lee HJ, et al. Tracking NF-kappaB activity in tumor cells during ovarian cancer progression in a syngeneic mouse model. J Ovarian Res. 2013;6(1):63. doi:10.1186/1757-2215-6-63.PubMedCentralPubMedCrossRef

22.

Wilson AJ, Liu AY, Roland J, Adebayo OB, Fletcher SA, Slaughter JC, et al. TR3 modulates platinum resistance in ovarian cancer. Cancer Res. 2013;73(15):4758–69. doi:10.1158/0008-5472.CAN-12-4560.PubMedCentralPubMedCrossRef

23.

Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul. 1984;22:27–55.CrossRef

24.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001;25(4):402–8. doi:10.1006/meth.2001.1262.PubMedCrossRef

25.

Everhart MB, Han W, Sherrill TP, Arutiunov M, Polosukhin VV, Burke JR, et al. Duration and intensity of NF-kappaB activity determine the severity of endotoxin-induced acute lung injury. J Immunol. 2006;176(8):4995–5005.PubMedCrossRef

26.

Stathopoulos GT, Sherrill TP, Han W, Sadikot RT, Yull FE, Blackwell TS, et al. Host nuclear factor-kappaB activation potentiates lung cancer metastasis. Mol Cancer Res. 2008;6(3):364–71. doi:10.1158/1541-7786.MCR-07-0309.PubMedCrossRef

27.

Khabele D, Fadare O, Liu AY, Wilson AJ, Wass E, Osteen K, et al. An orthotopic model of platinum-sensitive high grade serous fallopian tube carcinoma. Int J Clin Exp Pathol. 2012;5(1):37–45.PubMedCentralPubMed

28.

Khabele D, Son DS, Parl AK, Goldberg GL, Augenlicht LH, Mariadason JM, et al. Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy. Cancer Biol Ther. 2007;6(5):795–801.PubMedCrossRef

29.

Wilson AJ, Byun DS, Nasser S, Murray LB, Ayyanar K, Arango D, et al. HDAC4 promotes growth of colon cancer cells via repression of p21. Mol Biol Cell. 2008;19(10):4062–75. doi:10.1091/mbc.E08-02-0139.PubMedCentralPubMedCrossRef

30.

Connelly L, Barham W, Onishko HM, Sherrill T, Chodosh LA, Blackwell TS, et al. Inhibition of NF-kappa B activity in mammary epithelium increases tumor latency and decreases tumor burden. Oncogene. 2011;30(12):1402–12. doi:10.1038/onc.2010.521.PubMedCentralPubMedCrossRef

31.

Roepke M, Diestel A, Bajbouj K, Walluscheck D, Schonfeld P, Roessner A, et al. Lack of p53 augments thymoquinone-induced apoptosis and caspase activation in human osteosarcoma cells. Cancer Biol Ther. 2007;6(2):160–9.PubMedCrossRef

32.

Gurung RL, Lim SN, Khaw AK, Soon JF, Shenoy K, Mohamed Ali S, et al. Thymoquinone induces telomere shortening, DNA damage and apoptosis in human glioblastoma cells. PLoS One. 2010;5(8), e12124. doi:10.1371/journal.pone.0012124.PubMedCentralPubMedCrossRef

33.

Banath JP, Klokov D, MacPhail SH, Banuelos CA, Olive PL. Residual gammaH2AX foci as an indication of lethal DNA lesions. BMC Cancer. 2010;10:4. doi:10.1186/1471-2407-10-4.PubMedCentralPubMedCrossRef

34.

Karabela SP, Psallidas I, Sherrill TP, Kairi CA, Zaynagetdinov R, Cheng DS, et al. Opposing effects of bortezomib-induced nuclear factor-kappaB inhibition on chemical lung carcinogenesis. Carcinogenesis. 2012;33(4):859–67. doi:10.1093/carcin/bgs024.PubMedCentralPubMedCrossRef

35.

Aghajanian C, Blessing JA, Darcy KM, Reid G, DeGeest K, Rubin SC, et al. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2009;115(2):215–20. doi:10.1016/j.ygyno.2009.07.023.PubMedCrossRef

Title: Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer
Authors: Andrew J. Wilson
Jeanette Saskowski
Whitney Barham
Fiona Yull
Dineo Khabele
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Journal of Ovarian Research / Issue 1/2015
Electronic ISSN: 1757-2215
DOI: https://doi.org/10.1186/s13048-015-0177-8

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

Journal of ovarian research reviewer acknowledgement 2014

Retraction Note: Investigation of the hub genes and related mechanism in ovarian cancer via bioinformatics analysis

M-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patients

Risk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics

Identification of germ cell-specific VASA and IFITM3 proteins in human ovarian endometriosis

Regulatory T lymphocytes and transforming growth factor beta in epithelial ovarian tumors-prognostic significance